14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VKTX vs XNCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Viking Therapeutics, Inc (VKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VKTX carries a Unified Composite Score of 46.5/100 (HOLD) at $26.86 (N/M Forward P/E, 0.0% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin).
Composite vs. Pillar Nuance: While VKTX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. 0.0% operating margin) and revenue trajectory (+454.9% vs. +0.0% YoY).
Technical & Structure Timing Caution: VKTX is currently in a Breakdown options structure phase (RSI 47.2); meanwhile XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VKTX vs XNCR. Trailing 12-month operating profitability (VKTX 0.0% vs XNCR -72.7%) and valuation multiples (VKTX N/M vs XNCR 68.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment30.2% of Rev ($61M)
90D Engineering Disclosures0 Published
Investor FAQ VKTX vs XNCR Key Questions & Quantitative Answers
As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Viking Therapeutics, Inc (VKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VKTX carries a Unified Composite Score of 46.5/100 (HOLD) at $26.86 (N/M Forward P/E, 0.0% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin). Composite vs. Pillar Nuance: While VKTX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. 0.0% operating margin) and revenue trajectory (+454.9% vs. +0.0% YoY). Technical & Structure Timing Caution: VKTX is currently in a Breakdown options structure phase (RSI 47.2); meanwhile XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XNCR leads the Growth & Scale pillar: VKTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with XNCR at +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin). On trailing 12-month operating scale, VKTX generates N/A in USD-normalized revenue versus $200M for XNCR. In operating R&D and SG&A reinvestment, VKTX deploys N/A (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($61M) (0 disclosures) for XNCR.
XNCR screens cheaper on headline valuation multiples. VKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VKTX (-96.4% ROE) versus XNCR (-19.9% ROE) capital efficiency.
In options market volatility and institutional positioning, VKTX carries 164.2% implied volatility (88th %ile, Extreme (>80th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 74% Vol realized risk). By comparison, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.